Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517734 · ClinicalTrials.gov registry record
Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis
A clinical trial, sponsored by Cornell University.
- Completed
- Registry status
- 338
- Enrollment target
NCT04517734: Completed study, sponsored by Cornell University.
NCT04517734 is a clinical trial that has completed, run by Cornell University. The registered enrollment target is 338 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04517734 has completed, sponsored by Cornell University.
- COMPLETED
- Registry status
- 338 participants
- Enrollment target
Study Summary
Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2006-04 |
| Est. Completion | 2017-12 |
What the finished NCT04517734 record still lists
NCT04517734 is an observational study that tracks outcomes without assigning an intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04517734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04517734 about?
NCT04517734 is a clinical study titled "Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis". Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency an...
What is the current status of trial NCT04517734?
This trial is currently completed. The enrollment target is 338 participants. The study started on 2006-04. Estimated completion is 2017-12.
Who is sponsoring clinical trial NCT04517734?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia